Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Vein Occlusion: early-phase trial registry
3 of 12 indexed Retinal Vein Occlusion trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Retinal Vein Occlusion: 12 US clinical trials tracked, 3 recruiting.
Retinal Vein Occlusion is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 3 of these trials.
Enrollment posture brief
Registry condition retinal-vein-occlusion
OPEN 3 | RECR 25% | LATE 1 | EARLY 5 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Retinal Vein Occlusion lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Vein Occlusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Vein Occlusion is recruiting below its size-band peers.
3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinal Vein Occlusion research.
National Eye Institute (NEI) accounts for 3 of 12 trials (25%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Retinal Vein Occlusion enrolment sits around 120 participants.
Median target enrolment is 120 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Retinal Vein Occlusion research is mostly interventional.
9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
Johns Hopkins University
NCT04505618
National Eye Institute Biorepository for Retinal Diseases
National Eye Institute (NEI)
NCT01496625
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
MediBeacon
NCT04008121
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche
NCT05476926
Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage
National Eye Institute (NEI)
NCT00106132
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Barnes Retina Institute
NCT01428388
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
National Eye Institute (NEI)
NCT00101764
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Eyetech Pharmaceuticals
NCT00088283
30g vs 33g Needle for Intravitreal Injections
Wills Eye
NCT03038048
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
Optos
NCT01692938
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Novartis Pharmaceuticals
NCT04635800
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Annexin Pharmaceuticals AB
NCT05532735
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Vein Occlusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Vein Occlusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Vein Occlusion page
12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Retinal Vein Occlusion trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Retinal Vein Occlusion trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Vein Occlusion condition card totals 12 registered trials; most-linked intervention Triamcinolone Acetonide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.